BioXcel Therapeutics Inc. (NASDAQ: BTAI)
$0.3299
+0.0145 ( +9.24% ) 527.8K
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Market Data
Open
$0.3299
Previous close
$0.3154
Volume
527.8K
Market cap
$15.48M
Day range
$0.2890 - $0.3330
52 week range
$0.2890 - $4.1700
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | May 09, 2024 |
10-q | Quarterly Reports | 85 | May 09, 2024 |
def | Proxies and info statements | 8 | Apr 29, 2024 |
8-k | 8K-related | 50 | Apr 22, 2024 |
pre | Proxies and info statements | 6 | Apr 19, 2024 |
8-k | 8K-related | 22 | Apr 10, 2024 |
4 | Insider transactions | 1 | Apr 08, 2024 |
4 | Insider transactions | 1 | Apr 08, 2024 |
4 | Insider transactions | 1 | Apr 08, 2024 |
4 | Insider transactions | 1 | Apr 08, 2024 |